Cargando…
NYESO-1/LAGE-1s and PRAME Are Targets for Antigen Specific T Cells in Chondrosarcoma following Treatment with 5-Aza-2-Deoxycitabine
BACKGROUND: Chondrosarcoma has no proven systemic option in the metastatic setting. The development of a non-cross-resistant strategy, such as cellular immunotherapy using antigen-specific T cells would be highly desirable. NY-ESO-1 and PRAME are members of the Cancer Testis Antigen (CTA) family tha...
Autores principales: | Pollack, Seth M., Li, Yonqing, Blaisdell, Megan J., Farrar, Erik A., Chou, Jeffrey, Hoch, Benjamin L., Loggers, Elizabeth T., Rodler, Eve, Eary, Janet F., Conrad, Ernest U., Jones, Robin L., Yee, Cassian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3288075/ https://www.ncbi.nlm.nih.gov/pubmed/22384167 http://dx.doi.org/10.1371/journal.pone.0032165 |
Ejemplares similares
-
Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma
por: Jones, Robin L., et al.
Publicado: (2017) -
Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma
por: Dyrskjøt, L, et al.
Publicado: (2012) -
Immune-Based Therapies for Sarcoma
por: Pollack, Seth M., et al.
Publicado: (2011) -
Response to PD1 inhibition in conventional chondrosarcoma
por: Wagner, Michael J., et al.
Publicado: (2018) -
Lage entschärfen
por: Kemper, Christian
Publicado: (2020)